Migrasomes as intercellular messengers: potential in the pathological mechanism, diagnosis and treatment of clinical diseases

Qingfu Zhang, Jianyao Su, Zhichao Li, Su Yeon Han, Chuanhe Wang, Zhi‐Jun SunJournal of Nanobiotechnology 2025 · DOI

This review paper, published in the Journal of Nanobiotechnology, provides a comprehensive overview of migrasomes—a class of organelles discovered only a decade ago. It explores their life cycle, their role as "spatial-temporal" messengers in the body, and their emerging importance in diagnosing and treating diseases ranging from cancer to kidney failure.

TL;DR

Migrasomes are "pomegranate-like" organelles produced by migrating cells that act as specialized shipping containers for cellular information. This review highlights how these organelles coordinate complex processes like organ development and wound healing, while also being hijacked by viruses and tumors to spread infection and metastasis.

What Problem Does This Paper Address?

In the traditional view of cell biology, cells communicate primarily through direct contact or by secreting small vesicles (like exosomes). However, these methods don't fully explain how cells leave "breadcrumbs" or specific instructions at a particular location and time during movement.

Discovered in 2015, migrasomes fill this gap. They are large, membrane-bound structures that form on the "retraction fibers" (trailing tails) of moving cells. The challenge for researchers now is moving from basic discovery to clinical utility. This paper synthesizes a decade of research to explain the pathological mechanisms of migrasomes and evaluates their potential as non-invasive biomarkers and targeted drug delivery vehicles.

Methods

As a review article, the authors synthesized findings from over 160 primary research papers. They categorize the "life cycle" of a migrasome into five distinct biological stages:

  1. Nucleation: Driven by the enzyme SMS2 at the cell's leading edge.
  2. Maturation: Recruitment of Rab35 and integrins, which anchor the structure to the extracellular matrix.
  3. Expansion: TSPAN4 proteins stabilize the membrane, allowing it to swell.
  4. Vesicle Transport: Motor proteins (Myosin Va) pull "cargo" vesicles into the migrasome.
  5. Release: The final secretion of contents, a process termed migracytosis.

The paper also details the use of advanced imaging (Confocal and Transmission Electron Microscopy) and knockout models (e.g., Tspan4-deficient mice) used in the cited literature to prove these mechanisms.

Datasets

As this is a review paper, it does not introduce a new primary dataset. Instead, it references:

  • Animal Models: Zebrafish (organogenesis), mice (myocardial infarction, stroke, and cancer metastasis), and rabbits (retinopathy).
  • Clinical Samples: Human urine (for podocyte injury markers) and peripheral blood (for Cerebral Amyloid Angiopathy markers).
  • Bioinformatic Resources: Single-cell sequencing data from GEO and TCGA databases to correlate migrasome-related proteins (like TSPAN4) with disease prognosis.

Key Insights and Ideas

  • The "Pomegranate" Structure: Migrasomes are unique because they contain numerous smaller "intraluminal vesicles." This allows them to carry a complex cocktail of mRNA, proteins, and even damaged mitochondria.
  • Mitocytosis: The paper describes a fascinating quality-control mechanism where migrating cells "trash" their damaged mitochondria by shunting them into migrasomes. This prevents cellular aging and dysfunction.
  • Viral Trojan Horses: Viruses like Chikungunya and Vaccinia have evolved to hijack migrasomes. By hiding inside these organelles, viruses can spread from cell to cell while remaining shielded from the host's immune system and antiviral drugs.
  • Spatial Signaling: In embryonic development, migrasomes act as "signaling hubs." They are deposited at specific coordinates to create the chemical gradients necessary for organs to form in the right places.
  • Diagnostic Superiority: In kidney disease, the appearance of migrasomes in urine occurs before traditional markers like proteinuria, potentially allowing for much earlier intervention.

Key Results

  • Cancer Metastasis: High expression of migrasome-related proteins (e.g., CD151) is strongly correlated with poor prognosis in liver and pancreatic cancers, as they facilitate the "priming" of metastatic sites.
  • Cardiovascular Protection: Low-intensity pulsed ultrasound was shown to improve recovery after a heart attack by stimulating "mitocytosis" via migrasomes, clearing out damaged cellular components.
  • Neurological Biomarkers: In patients with Cerebral Amyloid Angiopathy (CAA), the percentage of TSPAN4+ monocytes in the blood correlates with the severity of cognitive impairment.
  • Regenerative Medicine: MSC-derived migrasomes containing the peptide dermcidin were found to be more effective at treating post-stroke pneumonia in mice than direct peptide injections, due to better stability and uptake.

Limitations and Future Work

The authors acknowledge several hurdles before migrasomes reach the clinic:

  • Preparation Difficulty: Because migrasome formation is strictly dependent on cell migration, they are harder to "manufacture" in a lab compared to exosomes.
  • Specificity: While migrasomes are promising biomarkers, researchers need to improve the sensitivity of detection methods to distinguish between migrasomes from different cell types in a single blood sample.
  • Bioengineering Gaps: There is currently a lack of research on how to efficiently load synthetic drugs into migrasomes for targeted therapy.

The paper concludes that the next frontier is "migrasome-mediated gene editing," potentially using these organelles to deliver CRISPR/Cas9 systems to specific diseased tissues.

Summary updated

Abstract

Migrasomes are newly identified organelles that were first discovered in 2015. Since then, their biological structure, formation process, and physiological functions have been gradually elucidated. Research in recent years has expanded our understanding of these aspects, highlighting their significance in various physiological and pathological processes. Migrasomes have been found to play crucial roles in normal physiological functions, including embryonic development, vascular homeostasis, material transport, and mitochondrial quality control. Additionally, emerging evidence suggests their involvement in various diseases; however, clinical research on their roles remains limited. Current studies indicate that migrasomes may contribute to disease pathogenesis and hold potential for diagnostic and therapeutic applications. This review consolidates existing clinical research on migrasomes, focusing on their role in disease mechanisms and their use in medical applications. By examining their biological structure and function, this review aims to generate insights that encourage further research, ultimately contributing to advancements in disease prevention and treatment.
BibTeX
@article{zhang2025migrasomes,
  author = {Qingfu Zhang and Jianyao Su and Zhichao Li and Su Yeon Han and Chuanhe Wang and Zhi‐Jun Sun},
  title = {{Migrasomes as intercellular messengers: potential in the pathological mechanism, diagnosis and treatment of clinical diseases}},
  journal = {Journal of Nanobiotechnology},
  year = {2025},
  doi = {10.1186/s12951-025-03362-6},
}
Figure